Overview of Gliclazide Sandoz

Property	Description
Active Ingredient	Gliclazide
Form	Modified-Release (MR) Oral Tablet
Pharmacological Class	Sulfonylurea, Oral Antidiabetic Agent
Common Use	Management of Type 2 Diabetes Mellitus
Origin	Synthetic Compound

Gliclazide Sandoz is a prescription-only, synthetic medication used to help adults manage Type 2 diabetes mellitus. Its identity is defined by its single active component, Gliclazide, which is classified as an oral antidiabetic agent belonging to the sulfonylurea pharmacological class. The medication is recognized for its importance in addressing public health needs for managing hyperglycemia, and Gliclazide is utilized globally as a core therapy for lowering blood sugar.

What Type of Medicine is Gliclazide Sandoz?

Gliclazide Sandoz functions as an insulin secretagogue, meaning its core function is to encourage the beta-cells in the pancreas to release more of the body's own existing insulin. The active ingredient, Gliclazide, achieves this by binding specifically to receptors on the pancreatic cells. This action is effective in restoring a more appropriate insulin response in people with Type 2 diabetes.

This mechanism fundamentally differs from antidiabetic drugs that solely improve the body's sensitivity to insulin or reduce the liver's glucose output. By directly boosting the available insulin, the drug helps facilitate the movement of glucose (sugar) from the blood into the body’s cells, which is the general purpose of taking the medication: to effectively lower and maintain stable blood glucose levels, such as when managing diet and activity have proven insufficient.

Gliclazide Sandoz: Form and Primary Action

The medication is most commonly available as an oral tablet, specifically utilizing a modified-release (MR) formulation. Gliclazide MR is designed as a prolonged-release tablet. The MR form is a key differentiating feature, designed to enhance patient convenience by allowing for once-daily dosing.

The modified-release tablet ensures a sustained and gradual release of the active ingredient, Gliclazide, into the body over an extended period after ingestion. This systemic delivery profile is crucial because it allows the medication to maintain consistent concentration, providing stable, long-term support for blood sugar control throughout the day from a single dose.

Regulatory References

WHO Model List of Essential Medicines

What side effects are possible with Gliclazide Sandoz?

Possible Side Effects and Safety Information

The safety profile of Gliclazide, the active ingredient in Gliclazide Sandoz, is established by government regulatory documents, focusing on adverse reactions and specific constraints.

Adverse Reaction Classification

Classification	Example Adverse Reactions (Regulatory Basis)
Common	Hypoglycaemia (low blood sugar), which is the most frequent adverse reaction due to the drug’s action as an insulin secretagogue.
Uncommon	Gastrointestinal disturbances, including abdominal pain, nausea, vomiting, dyspepsia, diarrhoea, and constipation.
Rare	Blood and lymphatic system disorders (e.g., changes in blood cell counts), serious skin reactions (e.g., bullous eruptions), and liver effects (e.g., cholestatic jaundice).

Serious Safety Concerns and Restrictions

Severe Hypoglycaemia is officially documented as a serious adverse reaction, capable of leading to confusion, coma, or death, and warrants careful consideration.

Adverse reactions are formally grouped into System-Organ Classes (SOC), including Metabolism and Nutrition Disorders (Hypoglycaemia), Gastrointestinal Disorders, and Dermatological Disorders, reflecting the body systems affected.

Safety notes specify that hypoglycaemic episodes may be more likely when meals are irregular or missed and may be more common upon treatment initiation. The medication is officially contraindicated in conditions such as severe renal or hepatic insufficiency, Type 1 Diabetes Mellitus, diabetic ketoacidosis, and concurrent use with systemic miconazole, as detailed in regulatory labels. These restrictions define the specific populations and conditions where the medicine's risks outweigh its use.

Overdose and Emergency Response

Overdose: When to Seek Help

Overdose of Gliclazide, a sulfonylurea, carries the principal risk of hypoglycemia (dangerously low blood sugar), which may be severe, prolonged, and recurrent.

Documented Manifestations

Symptom Category	Examples
Autonomic/Early	Sweating, trembling, rapid heart rate, intense hunger, nervousness.
Neuroglycopenic/Severe	Headache, confusion, loss of consciousness (coma), and convulsions (seizures).

Serious Outcomes and Emergency Action

Severe hypoglycemia from overdose is a life-threatening medical emergency. If not promptly corrected, it can lead to permanent neurological damage or death. The risk of severe and prolonged effects is increased in the elderly and in patients with impaired liver or kidney function.

If an overdose is suspected or known, immediate action is required. For mild symptoms, prompt consumption of oral sugar (carbohydrates) is the first step. However, urgent medical assistance or hospitalization is required for any suspected overdose, especially if symptoms are severe, include loss of consciousness, or persist after initial sugar intake. Healthcare providers may administer intravenous glucose and require continuous monitoring for 24 hours or longer due to the risk of recurrent hypoglycemia.

Therapeutic Uses of Gliclazide Sandoz

What Gliclazide Sandoz Treats: Main Uses and Benefits

Gliclazide Sandoz is used in the therapeutic management of Type 2 Diabetes Mellitus (T2DM) in adults. The drug is prescribed to provide sustained support when blood sugar control is not adequately maintained solely through changes in diet and physical activity.

The medication plays a role in managing the chronic state of hyperglycemia (persistently high blood glucose). It is applied across the clinical domain of Endocrinology and Metabolic Disease Management to reduce elevated blood sugar levels and achieve long-term stability, and is commonly used across clinical settings requiring additional symptomatic support.

The medication is used for managing physical symptoms commonly associated with high blood glucose, including excessive thirst (polydipsia) and frequent, increased urination (polyuria). The therapy contributes to easing the overall symptom load, which may assist with maintaining functional stability in the patient’s daily routine.

“The sustained regulation of blood sugar supports patients in coping more steadily with the common metabolic symptoms associated with their condition.”

Quick Fact: Relief for Osmotic Diuresis Symptoms The therapy is used for managing symptom clusters that create noticeable physiological strain, offering symptomatic relief that helps patients cope more steadily.

Regulatory References

Australian Therapeutic Goods Administration (TGA) product information

Eligibility and Restrictions for Use

Who Can and Cannot Use Gliclazide Sandoz?

This section outlines the official population eligibility and non-eligibility rules for Gliclazide Sandoz, strictly as documented in governmental regulatory sources.

Contraindicated Populations (Must Not Use)

Official regulatory documents state that Gliclazide Sandoz is contraindicated and must not be used in specific patient groups, including:

Patients with Type 1 Diabetes Mellitus (Insulin-Dependent Diabetes).
Those experiencing diabetic ketoacidosis or diabetic coma.
Patients with severe hepatic impairment (liver failure) or severe renal impairment (kidney failure).
Individuals with known hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides.
Women who are pregnant or who are breast-feeding (lactating).
Patients taking the antifungal medicine systemic miconazole.

Eligibility and Restrictions

Category	Official Eligibility Status
Indicated Age Group	Adults (18 years and older) with Type 2 Diabetes Mellitus.
Pediatric Use	Not recommended for children and adolescents (under 18 years); safety and effectiveness are not established.
Organ Function	Permitted in mild to moderate renal impairment; however, caution is required, and use is prohibited in severe impairment.
Acute Stress	Must be temporarily discontinued during serious infection, trauma, or surgery.

Eligibility for use is strictly defined by these label-based rules.

What should I know about interactions with other medicines?

The interaction profile for Gliclazide Sandoz is defined by its potential to cause either a substantial increase or a decrease in its blood glucose-lowering action, as documented in official regulatory information.

Interaction Classification	Interacting Substance/Agent	Documented Outcome/Basis
Contraindicated	Miconazole (Systemic or Oromucosal Gel)	Formal prohibition due to significant potentiation and risk of severe hypoglycaemic coma.
Not Recommended	Phenylbutazone (Systemic)	Increases action by displacing Gliclazide from plasma protein binding and/or reducing its clearance.
Not Recommended	Alcohol (Ethanol)	Potentiates the hypoglycaemic reaction by inhibiting the body's compensatory mechanisms.

Interaction with other medicinal products requires monitoring based on two main outcomes. Agents that may potentiate the hypoglycaemic effect include Beta-Blockers, ACE Inhibitors, NSAIDs, and MAOIs. Conversely, agents that may attenuate the effect and increase blood glucose levels include Glucocorticoids, Danazol, and high-dose Chlorpromazine. Furthermore, the use of St John’s Wort preparations may affect blood glucose control. A population-specific caution is noted for patients with severe hepatic or renal insufficiency where altered pharmacokinetics and/or pharmacodynamics increase the risk of severe hypoglycemia.

Mechanism of Action

How Gliclazide Sandoz Works

The action of Gliclazide, the active ingredient in Gliclazide Sandoz, is rooted in its highly specific interaction with the insulin-producing cells of the pancreas, categorized as an insulin secretagogue mechanism.

Direct Modulation of the Pancreatic K ATP Channel

Gliclazide exerts its effect by binding to the Sulfonylurea Receptor 1 ( SUR1) subunit of the ATP-sensitive potassium channel ( K ATP channel) on the beta-cell membrane. This molecular interaction physically blocks the channel, inhibiting the outward flow of potassium ions. This immediate cellular effect is the necessary trigger for the subsequent cascade that follows.

The Insulin Secretion Cascade and Systemic Effect

The blockage of the K ATP channel leads to membrane depolarization, which in turn opens voltage-gated calcium channels, prompting a rapid influx of calcium ions. The elevated intracellular calcium acts as a signal for the exocytosis (release) of stored insulin granules. The physiological consequence of this direct mechanism is an increase in the amount of insulin circulating in the bloodstream, facilitating glucose uptake by peripheral tissues and modulating systemic glucose metabolism.

Dosage and Administration Information

How to Use Gliclazide Sandoz

The Gliclazide Sandoz modified-release (MR) tablet is prescribed for oral administration as a continuous therapy for Type 2 Diabetes Mellitus. The usage pattern establishes a standard regimen that is followed for the medication's intended long-term effect.

Official Dosing and Frequency

Regimen Element	Official Guideline
Route of Administration	Oral route only.
Dosing Frequency	Once daily.
Starting Dose	30 mg once daily.
Maximum Daily Dose	120 mg.

The daily dose may range from 30 mg to 120 mg, taken in a single, un-divided intake. Dose adjustments typically occur in 30 mg increments and are generally performed after a minimum interval of one month to assess control.

Administration Requirements

Administration is contingent on taking the medication with breakfast to ensure proper intake conditions and help maintain consistent plasma concentrations throughout the day.

Procedural Requirement	Official Instruction
Tablet Handling	Tablets must be swallowed whole with water; they must not be crushed or chewed to preserve the modified-release profile.
Missed Dose Rule	If a dose is missed, the user must not increase the dose taken the following day to compensate.

The standard adult dosing regimen is also applied to older adults (aged 65 years and above), as there is no specified requirement for a general initial dose reduction for this population. Conversely, the safety and efficacy of Gliclazide MR have not been established for pediatric use.

Recent Clinical Evidence

Gliclazide Sandoz: Recent Clinical Evidence

Evidence for Use in Glycemic Control

Research has been studied for its application in Type 2 Diabetes to evaluate measured changes related to blood sugar control in adults with this condition. The evidence primarily involves short-term to intermediate-term Randomized Controlled Trials (RCTs), where patients were observed over defined time intervals up to two years. These trials research examined key outcomes such as the change in the average blood sugar marker, Glycated Hemoglobin (HbA1c), and related blood sugar measurements. Studies explored Gliclazide both when used alone and in combination with other oral diabetes medicines. Findings from these studies report how blood sugar markers evolved in the observed populations, and data show patterns related to these measurements. However, the methodological quality of some comparative RCTs, and the variability of their design, was observed in some studies as a research limitation.

Evidence for Long-Term Vascular Outcomes

Research was studied for its use as part of a strategy focused on intensive blood sugar control over the long term, primarily in a single, large-scale, long-term RCT with follow-up periods extending up to several years. The main study outcomes were evaluated in relation to long-term systemic or functional imbalance, specifically looking at the frequency of Major Macrovascular Events (like heart attack or stroke) and Major Microvascular Events (such as diabetic nephropathy). Studies reported specific measurements of the frequency of these long-term outcomes. However, conflicts observed between observational data and randomized trial data mean that certainty remains low when applying results to general, real-world populations.

Evidence in Special Study Populations and Uncertainty

Research has been studied for its use in specific patient subgroups. Studies explored populations presenting with conditions characterized by functional limitations, particularly adults who also had chronic kidney disease (CKD). The findings from these trials provide context regarding the measured outcomes in these specific groups. Additionally, research has been studied for its use in older adult populations. A primary research limitation frame is that evidence quality varies across studies, and there is limited information for long-term outcomes beyond the major dedicated studies. Overall, research provides context but does not determine whether an individual will respond similarly to the patterns observed in the large group trials.

Key Studies & References

Type 2 diabetes in adults: management (NICE Guideline NG28)

Frequently Asked Questions (FAQ)

Common questions about Gliclazide Sandoz (FAQ)

Q: Is Gliclazide Sandoz the same as just Gliclazide?

Gliclazide is the official name of the active pharmaceutical ingredient (API) that performs the medicine's function. Gliclazide Sandoz is the trade name given to the final product by the manufacturer Sandoz. Official product information describes the medicine in terms of its active ingredient, Gliclazide.

Q: Do you always have to take Gliclazide Sandoz for type 2 diabetes?

Treatment for Type 2 Diabetes Mellitus is considered a continuous, long-term therapy by regulatory documents. The official product information specifies Gliclazide Sandoz is prescribed for continuous therapy. Discontinuation or change in therapy is a medical decision that requires consultation with a healthcare professional.

Q: What is the difference between Gliclazide and Metformin?

Gliclazide belongs to a class of medicines called sulfonylureas, and its function is described as an insulin secretagogue. This means its described action is stimulating the pancreas to release more of the body’s own existing insulin. Other oral antidiabetic agents, such as Metformin, are classified differently, as they primarily work by reducing the liver's glucose production.

Q: Is Gliclazide Sandoz known to cause weight gain?

Official safety information for medicines in the sulfonylurea class, which includes Gliclazide, lists weight gain as a possible adverse effect. Weight gain is one of the factors acknowledged when managing Type 2 diabetes.

Q: How quickly does Gliclazide Sandoz start to work after taking it?

Gliclazide Sandoz is an extended- or modified-release (MR) formulation. This design ensures a gradual and sustained release of the active ingredient into the body over many hours after ingestion. This systemic delivery profile is intended to provide stable, long-term support for blood sugar control throughout the day from a single dose.

Q: Is it safe to drive after taking Gliclazide Sandoz?

Official guidelines advise that hypoglycaemia (low blood sugar), which is a common side effect of Gliclazide, can impair concentration and slow reaction time. Official product information indicates that caution or avoidance of activities like driving is warranted if signs of low blood sugar are experienced.

Q: Is Gliclazide Sandoz safe for elderly patients?

The medication is used in older adult populations (aged 65 years and above). However, official regulatory texts advise caution in this population, as the risk and recognition of low blood sugar (hypoglycaemia) may be increased in older patients.

Q: Are there different forms of Gliclazide Sandoz tablets, like immediate or modified release?

The official product information describes Gliclazide Sandoz as a modified-release (MR) tablet, which is designed to enhance patient convenience by allowing for once-daily dosing. The regulatory documents focus specifically on this prolonged-release formulation.

Q: Does Gliclazide Sandoz help with non-diabetic conditions?

The only official purpose for Gliclazide Sandoz, as stated in regulatory documents, is the management of Type 2 Diabetes Mellitus in adults. It is not approved or indicated for use in non-diabetic conditions.

Q: Is it normal to feel dizzy when first starting Gliclazide Sandoz?

Dizziness is a known symptom associated with hypoglycaemia (low blood sugar), which is the most frequent adverse effect of Gliclazide. Official documents note that hypoglycaemic episodes may be more common when treatment is first initiated.

Q: What are the possible signs of an allergic reaction to Gliclazide Sandoz?

The official documents mention serious safety concerns such as severe hypersensitivity to Gliclazide or related medicines. Serious adverse reactions can include severe skin reactions, such as blistering rashes and bullous eruptions. These serious adverse reactions are formally reported conditions that warrant prompt consultation with a medical professional.

Q: Are there any specific lifestyle changes mentioned in the research for Gliclazide Sandoz?

Official patient information often emphasizes that treatment with Gliclazide Sandoz should be complemented by key lifestyle factors. Official information mentions that following dietary advice and taking regular physical exercise are important supportive components for effective blood glucose control.

Q: Is it possible to become resistant to the effects of Gliclazide Sandoz over time?

Official regulatory documents acknowledge a possibility known as 'secondary failure.' This refers to a situation where the medication becomes less effective after an initial period of successful blood sugar control. This is a recognized factor in the long-term management of Type 2 diabetes.

Q: What types of heart issues or conditions might prevent someone from using Gliclazide Sandoz?

Official contraindications focus primarily on certain diabetes complications and organ failures, such as diabetic keto-acidosis and severe hepatic or renal impairment. However, official information also notes that the medicine should be temporarily discontinued during periods of acute stress, such as severe infection, trauma, or surgery.

Q: Is Gliclazide Sandoz known to cause any long-term vision problems?

Official adverse reaction reports include transient visual disturbances as a possible effect, which are often related to fluctuations in blood glucose levels. The regulatory information does not list long-term, non-transient vision loss as a primary side effect of Gliclazide.

Q: Do patients typically need to monitor their blood sugar more often when starting Gliclazide Sandoz?

Official safety information recommends regular monitoring of both blood glucose levels and the average blood sugar marker, HbA1c. The frequency of this monitoring may be increased when treatment is first started or when changes in the prescribed regimen are made.

Q: Is it described as being suitable for patients with mild liver impairment?

Official regulatory texts explicitly state that the medicine is contraindicated and must not be used in cases of severe hepatic (liver) impairment. The documents do not specify a definitive status for mild liver impairment, though caution is generally advised when organ function is altered.

Q: Are there differences in the clinical research for the modified release versus standard tablet?

The modified-release (MR) formulation is a key feature of the medication, and research specifically supports its unique design. The clinical trials confirm that the MR form achieves a sustained concentration of Gliclazide to provide stable, once-daily blood glucose control, which is the basis for its approved use.

Q: What is the general expectation for how much Gliclazide Sandoz lowers blood sugar levels?

Clinical studies have confirmed Gliclazide's effectiveness in lowering the average blood sugar marker, Glycated Hemoglobin (HbA1c), over time, whether used alone or with other oral agents. The exact amount of reduction observed can vary significantly between individual patients and different clinical trials.

How should Gliclazide Sandoz be stored and disposed of?

Storage and Disposal Requirements for Gliclazide Sandoz

Gliclazide Sandoz modified-release tablets must be stored according to regulatory specifications to ensure stability and safety. The official labeled storage temperature requires the medicine to be kept below 25 C or 30 C, depending on the formulation and region, and it should not be frozen.

Storage Conditions

Protection: Keep the tablets in the original container (blister pack or bottle) to protect them from moisture and light.
Safety: Always store the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Gliclazide Sandoz must be discarded in accordance with local requirements. The official label directs that the medicine should not be thrown away via wastewater or household waste to protect the environment. Return leftover tablets to a pharmacist or designated collection point for appropriate disposal.

Gliclazide Sandoz